BCR-ABL positive chronic myeloid leukemia with concurrent JAK2 V617F positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T)

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 306-307

  Gattenlohner, Stefan ^a   Völker, Hans Ulrich ^a   Etschmann, Benjamin ^a   Einsele, Hermann ^a   Müller Hermelink, Hans Konrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; LACTATE DEHYDROGENASE;

AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT RESPONSE;

EID: 65649152398     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21296     Document Type: Article

References (5)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 world health organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
2. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008;22:1059-1062.
3. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008;93:34-40.
4. Gattenlohner S, Serfling E, Einsele H, et al. Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F. Leukemia 2008. [Epub ahead of print].
5. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006;108:1377-1380.